Latest

States, Cities Expand “Sunshine” Requirements

The federal Open Payments program is finally reaching its goal—to halt the adoption of multiple “transparency” initiatives by states and local governments with a national system for collecting and disclosing data on industry payments. Will it make a difference?

The Man with a Price: ICER's Steven Pearson

Everyone’s talking value, but not everyone is willing to pin down the elusive concept. Pharm Exec talks with Steven Pearson, founder of the Institute for Clinical Effectiveness Review (ICER), about all things value-based.

Dealmaking in 2017: Striking a Balance

Experts assess the current pharma dealmaking landscape—one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.

PharmExec Videos

New & Noteworthy

Beyond the Science: Commercial Implications From ASCO 2017

Four strategic takeaways from this year's event that are important for pharma oncology leaders, by Maria Whitman and Sharon Karlsberg.

Health Policy Problem Solver: Fumie Griego

IFPMA's new Assistant Director General speaks about her mission to use the organization’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

News Spotlight: Pharma

Pharm Exec’s 13th Annual Press Audit reveals a tonal undercurrent in sync with an industry unable to escape the glare of scrutiny.

Unraveling the Potential of Real-World Studies

The significance of real-world data has been not utilized to the full potential, writes Uttam Barick.

Sales & Marketing

The 'Hear' and Now for Pharma and Social Media

For the life sciences industry in 2017, engaging across social media means less talking—and more listening. Peter Houston reports.

Customer Engagement: A Key Upgrade in Brand Planning for a Multi-Channel World

Gregg Fisher reflects on how brand planning can be enhanced to better serve brand and product managers to deliver on the promises of “customer-centric” and “multi-channel” communications.

Decoding the Disruption: Making Meaningful Marketing Out of Top Trends

Separating the meaningful from the merely novel, Bill Drummy outlines his Top Ten digital marketing trends for 2017.

Featured E-Books

Bright Skies, Big Challenges: Orphan Drugs and Rare Diseases

From the editors of Pharmaceutical Executive, check out the latest e-book discussing the state and future of Rare and Orphan Diseases. Download the e-book.

 

Securing the Global Supply Chain: Strategies for Operational Excellence

Strategic management of the supply chain is vital to winning with customers. Cost and quality are important, but they are not the only things customers care about: New services, flexibility in  relationships, supply reliability, and creatively overcoming obstacles in delivery of products are also core values. Pharmaceutical product portfolios and customers are becoming more complex. To stay ahead, customer-focused supply-chain capabilities is becoming an increasingly crucial part of a company’s competitive advantage. Download the e-book.

 

The Changing Contours of Drug Commercialization

"The Changing Contours of Drug Commercialization," a new e-book from the editors of Pharmaceutical Executive, sheds light on solutions and strategies uniquely within a manufacturer's own sphere of control that can help navigate the often unforgiving transition from registration to the real-world battle for clinical acceptance and market share. Download the e-book.

 

 

View all e-books

PEspeaks

Value Creation Powered by Data

In the first of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Creation.

Pharma’s Marijuana Makeover

As more states approve the use of medical marijuana—and its rising profile as potential opioid alternative—industry and FDA are stepping up their focus on developing cannabis-derived therapies.

Brexit and the EMA: Bidding and Betting on an Uncertain Future

A review of the top contenders to land the agency as decision on its relocation draws closer.

Pressure Mounts on FDA, Pharma to Tackle Opioid Abuse

The growing toll requires new assessment of risks, expanded provider education, and more scrutiny of marketed products.

Compliance Top of Mind

There is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry. The articles from Pharmaceutical Executive provide a look at the latest in compliance for marketing, labeling, and export control, as well as offer tips to stay compliant in the coming years.
 

Read More.

Interviews

The Man with a Price: ICER's Steven Pearson

Everyone’s talking value, but not everyone is willing to pin down the elusive concept. Pharm Exec talks with Steven Pearson, founder of the Institute for Clinical Effectiveness Review (ICER), about all things value-based.

Improving Patients’ Lives and Boosting Mature Product Portfolios

Q&A with Merck KGaA’s Simon Sturge spotlights the development of one injection device that is helping change the treatment-adherence landscape.

Executive Roundtable: Where is Your Physician?

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

Compliance in the Pharmaceutical Industry: A Marketer's Perspective

Interacting with HCPs is fraught with compliance challenges. This article takes a deep dive the implications of compliance for marketers in a world where new technologies being created every day.

Regulatory

States, Cities Expand “Sunshine” Requirements

The federal Open Payments program is finally reaching its goal—to halt the adoption of multiple “transparency” initiatives by states and local governments with a national system for collecting and disclosing data on industry payments. Will it make a difference?

Congress Meets Deadline for Reauthorizing FDA User Fees

Jill Wechsler on the Senate's 94-1 vote to approve legislation reauthorizing user fees and a series of program changes to maintain a smoothly functioning FDA product review and approval process.

Brexit and the EMA: Bidding and Betting on an Uncertain Future

A review of the top contenders to land the agency as decision on its relocation draws closer.

Pressure Mounts on FDA, Pharma to Tackle Opioid Abuse

The growing toll requires new assessment of risks, expanded provider education, and more scrutiny of marketed products.

From the Editor

Pharma’s Marijuana Makeover

As more states approve the use of medical marijuana—and its rising profile as potential opioid alternative—industry and FDA are stepping up their focus on developing cannabis-derived therapies.

The 1, 2, 3’s of VBCs

As we step further into the waters of value-based contracting arrangements, lessons learned must be shared—including the role of the patient in the equation.

Talent That Takes You into the Future

There's no shortage of talent, expertise and passion in the biopharma industry. It's time for that talent to shine, writes Lisa Henderson.

lorem ipsum